Evaluation of reboxetine, a noradrenergic antidepressant,
for the treatment of fibromyalgia and chronic low back pain
by
Krell HV, Leuchter AF, Cook IA, Abrams M.
Laboratory of Behavioral Pharmacology,
UCLA Neuropsychiatric Institute, 37-452 NPI,
760 Westwood Plaza, Los Angeles, CA 90024, USA.
hkrell@mednet.ucla.edu
Psychosomatics. 2005 Sep-Oct;46(5):379-84.

ABSTRACT

Clinical experience supports the use of antidepressant medications to treat chronic pain syndromes, such as low back pain and fibromyalgia. Although this use of antidepressants is common in clinical practice, the literature supporting this off-label use has some limitations. In this report, the authors review the body of clinical data on the use of antidepressants in treating pain and present a case series of depressed patients with these syndromes who experienced relief of pain symptoms while being treated with the noradrenergic antidepressant reboxetine. These subjects experienced significant relief of pain before any significant improvement in actual mood symptoms. Our experience with reboxetine suggests that this noradrenergic antidepressant may have efficacy in the treatment of chronic pain in patients with depression.

Selectivity
Reboxetine
NARIs v SSRIs
Switching from Prozac
Reboxetine: product info
Noradrenergic antidepressants
Noradrenaline and cerebral aging
Reboxtine versus fluoxetine (Prozac)
Reboxetine (Edronax) plus escitalopram (Lexapro)

Refs
and further reading

HOME
HedWeb
Nootropics
cocaine.wiki
Future Opioids
BLTC Research
MDMA/Ecstasy
Superhapiness?
Utopian Surgery?
The Abolitionist Project
The Hedonistic Imperative
The Reproductive Revolution
Critique of Huxley's Brave New World

The Good Drug Guide
The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family